The round was led by MAHR Projects, Richard Pennycook CBE, and Tim Score to fuel platform expansion and virtual event growth.
"There was a big shift in people’s attitudes towards virtual events in the latter half of 2020, as people realised that interactive activities such as cooking classes, escape rooms or cocktail making lessons can be engaging and great fun. As we go into another lockdown and the continuation of remote working, virtual events are here to stay and we’re going to make sure the very best experiences are available on Feast It."
The London insurtech has drawn backing from Shell Ventures and Marbruck Investments to drive domestic and international growth.
"Partnering with Shell Ventures brings not only fresh capital, but also an investor with a thriving global connected fleet business and expertise to share. We are looking forward to working with Shell and bringing our class-leading motor fleet insurance product with explainable exposure-based pricing to an even wider audience"
The expense platform secured the capital from a Seedrs campaign and the Future Fund.
"We are excited to announce this latest funding round and overwhelmed with the drive and support behind the Seedr campaign. We go into 2021 with a strong proposition as we continue using the power of Open Banking technology to drive our product innovation."
The seed round was led by Hoxton Ventures with backing from dRx Capital and Founders Factory.
"Our sole focus at Peptone is to embrace experimental failure and, in fact, acknowledge it as an absolutely vital stage in the process of getting the design of protein-based medicines right. Great science is always born out of failure. The reality is that drug discovery in Big Pharma sees only a small fraction of protein based drugs pass the preclinical stages due to their complexity. Pharma, just like any industry, is subject to the ‘power law’. A small number of innovative drugs generate disproportional benefits to patients and outsized capital returns. We are working on shifting this failure-to-success ratio in a meticulously predictable and repeatable way using the best computational methods and scalable data science. Only last week one of our clients produced a monoclonal antibody for which our platform suggested seven radical mutations. The said therapeutic protein got vastly improved. The probability of a human researcher being able to engineer this type of change is equal to 1/1,280,000,000. In layman terms you are four times more likely to win the Powerball lottery than to spontaneously find the solution our platform has identified in less than ten days. The business of protein therapeutics is a huge industry and as we grow and further develop our supercomputing capacity we can help make significant progress in the time to market for much sought-after protein-based treatments."
The London-based property platform secured the capital to fund team expansion, technology development, and a secondary market launch.
"This is a great start to 2021 and a clear demonstration of the belief investors have in the future of this business and in the property sector in general, despite the uncertainty that was caused by the pandemic and Brexit."
